(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
The Best 15 Applications for Efficiency and Association - 2Wegovy maker Novo sharpens consumer focus with board role for Mars CEO
- 3Ringleader of suspected human trafficking network arrested in Ethiopia
- 421 Things You Ought to Never Share with Your Childless Companion
- 5Israeli naval intelligence reduces Iranian threat to Strait of Hormuz
- The Best 10 Innovation Advancements of the Year
- Sports Shoes of 2024: Upgrade Execution and Solace
- Wegmans recalls mixed nuts over salmonella contamination fears
- Which Exhibition hall Do You Suggest? Vote
- Vote In favor of Your Favored Video Conferencing Administration
- Humpback whale stranded on Germany's Baltic coast frees itself
- Best Getaway destination: Ocean side, Mountain, or City
- Ghassan Al-Duhaini to replace Abu Shabab as Popular Forces leader in Gaza
- I'm a woman who's into weightlifting. Was I man enough for the creatine-packed 'Man Cereal'?
